webinar
Oct. 27-28, 2025, Boston, MA, USA - Booth 114.
Read More

Fmoc-N-Me-Lys(N3)-OH

  CAS No.: 1263721-14-7   Cat No.: BADC-01976 4.5  

Fmoc-N-Me-Lys(N3)-OH is an azide-functionalized, methylated lysine derivative used as an ADC linker building block, improving site-specific click conjugation and payload attachment in antibody-drug conjugates.

Fmoc-N-Me-Lys(N3)-OH

Structure of 1263721-14-7

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
ADC Linker
Molecular Formula
C22H24N4O4
Molecular Weight
408.5

* For research and manufacturing use only. We do not sell to patients.

Size Price Stock Quantity
-- $-- In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

Popular Publications Citing BOC Sciences Products
IUPAC Name
(2S)-6-azido-2-[9H-fluoren-9-ylmethoxycarbonyl(methyl)amino]hexanoic acid
Canonical SMILES
CN(C(CCCCN=[N+]=[N-])C(=O)O)C(=O)OCC1C2=CC=CC=C2C3=CC=CC=C13
InChI
InChI=1S/C22H24N4O4/c1-26(20(21(27)28)12-6-7-13-24-25-23)22(29)30-14-19-17-10-4-2-8-15(17)16-9-3-5-11-18(16)19/h2-5,8-11,19-20H,6-7,12-14H2,1H3,(H,27,28)/t20-/m0/s1
InChIKey
DJQVUFFDGFWHHQ-FQEVSTJZSA-N

Fmoc-N-Me-Lys(N3)-OH is a specialized reagent used in peptide synthesis and chemical biology. Here are some key applications of Fmoc-N-Me-Lys(N3)-OH:

Peptide Synthesis: Fmoc-N-Me-Lys(N3)-OH is integral to the synthesis of peptides with specific functional groups. Its incorporation allows the introduction of azide functionality, which can be further modified using click chemistry reactions. This versatility is crucial for creating peptides with customized properties for research and therapeutic applications.

Cross-linking Studies: The azide group in Fmoc-N-Me-Lys(N3)-OH makes it an excellent candidate for cross-linking studies. Through bioorthogonal reactions, researchers can form stable linkages between peptides or proteins, enabling the study of protein interactions and structures. This methodology is valuable in structural biology and proteomics.

Drug Delivery Systems: Fmoc-N-Me-Lys(N3)-OH can be employed in the design of targeted drug delivery systems. By incorporating this reagent into peptide scaffolds, researchers can attach therapeutic agents or imaging probes via the azide group. This leads to the development of advanced drug delivery vehicles with high specificity and efficiency.

Bioconjugation: The unique properties of Fmoc-N-Me-Lys(N3)-OH make it suitable for bioconjugation techniques. It can be used to attach various biomolecules such as sugars, lipids, or other peptides through click chemistry. This enables the creation of multifunctional biomaterials and conjugates for diverse biological and medical applications.

1. Reaction of hydroxyl radicals with azacytosines: a pulse radiolysis and theoretical study
G Pramod, K P Prasanthkumar, Hari Mohan, V M Manoj, P Manoj, C H Suresh, C T Aravindakumar J Phys Chem A. 2006 Oct 12;110(40):11517-26. doi: 10.1021/jp063958a.
Pulse radiolysis and density functional theory (DFT) calculations at B3LYP/6-31+G(d,p) level have been carried out to probe the reaction of the water-derived hydroxyl radicals (*OH) with 5-azacytosine (5Ac) and 5-azacytidine (5Acyd) at near neutral and basic pH. A low percentage of nitrogen-centered oxidizing radicals, and a high percentage of non-oxidizing carbon-centered radicals were identified based on the reaction of transient intermediates with 2,2'-azinobis(3-ethylbenzothiazoline-6-sulfonate), ABTS2-. Theoretical calculations suggests that the N3 atom in 5Ac is the most reactive center as it is the main contributor of HOMO, whereas C5 atom is the prime donor for the HOMO of cytosine (Cyt) where the major addition site is C5. The order of stability of the adduct species were found to be C6-OH_5Ac*>C4-OH_5Ac*>N3-OH_5Ac*>N5-OH_5Ac* both in the gaseous and solution phase (using the PCM model) respectively due to the additions of *OH at C6, C4, N3, and N5 atoms. These additions occur in direct manner, without the intervention of any precursor complex formation. The possibility of a 1,2-hydrogen shift from the C6 to N5 in the nitrogen-centered C6-OH_5Ac* radical is considered in order to account for the experimental observation of the high yield of non-oxidizing radicals, and found that such a conversion requires activation energy of about 32 kcal/mol, and hence this possibility is ruled out. The hydrogen abstraction reactions were assumed to occur from precursor complexes (hydrogen bonded complexes represented as S1, S2, S3, and S4) resulted from the electrostatic interactions of the lone pairs on the N3, N5, and O8 atoms with the incoming *OH radical. It was found that the conversion of these precursor complexes to their respective transition states has ample barrier heights, and it persists even when the effect of solvent is considered. It was also found that the formation of precursor complexes itself is highly endergonic in solution phase. Hence, the abstraction reactions will not occur in the present case. Finally, the time dependent density functional theory (TDDFT) calculations predicted an absorption maximum of 292 nm for the N3-OH_5Ac* adduct, which is close to the experimentally observed spectral maxima at 290 nm. Hence, it is assumed that the addition to the most reactive center N3, which results the N3-OH_5Ac* radical, occurs via a kinetically driven process.
2. On the Heterogeneous Nature of Cisplatin-1-Methyluracil Complexes: Coexistence of Different Aggregation Modes and Partial Loss of NH3 Ligands as Likely Explanation
Sonja Pullen, Alexander Hegmans, Wolf G Hiller, André Platzek, Eva Freisinger, Bernhard Lippert ChemistryOpen. 2021 Jan;10(1):28-45. doi: 10.1002/open.202000317.
The conversion of the 1 : 1-complex of Cisplatin with 1-methyluracil (1MeUH), cis-[Pt(NH3 )2 (1MeU-N3)Cl] (1 a) to the aqua species cis-[Pt(NH3 )2 (1MeU-N3)(OH2 )]+ (1 b), achieved by reaction of 1 a with AgNO3 in water, affords a mixture of compounds, the composition of which strongly depends on sample history. The complexity stems from variations in condensation patterns and partial loss of NH3 ligands. In dilute aqueous solution, 1 a, and dinuclear compounds cis-[(NH3 )2 (1MeU-N3)Pt(μ-OH)Pt(1MeU-N3)(NH3 )2 ]+ (3) as well as head-tail cis-[Pt2 (NH3 )4 (μ-1MeU-N3,O4)2 ]2+ (4) represent the major components. In addition, there are numerous other species present in minor quantities, which differ in metal nuclearity, stoichiometry, stereoisomerism, and Pt oxidation state, as revealed by a combination of 1 H NMR and ESI-MS spectroscopy. Their composition appears not to be the consequence of a unique and repeating coordination pattern of the 1MeU ligand in oligomers but rather the coexistence of distinctly different condensation patterns, which include μ-OH, μ-1MeU, and μ-NH2 bridging and combinations thereof. Consequently, the products obtained should, in total, be defined as a heterogeneous mixture rather than a mixture of oligomers of different sizes. In addition, a N2 complex, [Pt(NH3 )(1MeU)(N2 )]+ appears to be formed in gas phase during the ESI-MS experiment. In the presence of Na+ ions, multimers n of 1 a with n=2, 3, 4 are formed that represent analogues of non-metalated uracil quartets found in tetrastranded RNA.
3. Tautomeric modification of GlcNAc-thiazoline
Spencer Knapp, Mohannad Abdo, Kehinde Ajayi, Richard A Huhn, Thomas J Emge, Eun Ju Kim, John A Hanover Org Lett. 2007 Jun 7;9(12):2321-4. doi: 10.1021/ol0706814. Epub 2007 May 18.
The potent O-GlcNAcase (OGA) inhibitor GlcNAc-thiazoline has been modified by buffer- or acylation-induced imine-to-enamine conversion and then electrophile or radical addition (Xn = D3, F, N3, OH, SMe, COCF3, CF3). Several functionalized GlcNAc-thiazolines show highly selective inhibition of OGA vs human hexosaminidase and thus have promise as tools for targeted investigations of OGA, an enzyme linked to diabetes and neurodegeneration. A new radical addition/fragmentation reaction of the N-(trifluoroacetyl)enamine has been discovered.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Related Products

Contact our experts today for pricing and comprehensive details on our ADC offerings.

You May Also Be Interested In

From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.

ADC Linker Development Enzyme Cleavable Linker Cathepsin B Cleavable Linker/Peptide Linker Phosphatase Cleavable Linker β-Glucuronide Linker β-Galactosidase Cleavable Linker Sulfatase Cleavable Linker Chemically Cleavable Linker Non-Cleavable Linker Services Acid Cleavable Linker/Hydrazone Linker

Unlock Deeper ADC Insights

Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.

Linkers - A Crucial Factor in Antibody–Drug Conjugates In-Depth Review of ADC Linkers: Types, Mechanisms, and Research Progress New Structural Insights Solve Instability Issues of Maleimide Linkers in ADCs PEG Linkers in Antibody-Drug Conjugates Peptide Linkers in Antibody-Drug Conjugates Disulfide Linkers in Antibody-Drug Conjugates Biotinylation Reagents in Antibody-Drug Conjugates Maleimide Linkers in Antibody-Drug Conjugates Current ADC Linker Chemistry SPDB Linkers in Antibody-Drug Conjugates

Explore More ADC Products

Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.

ADC Cytotoxin

Powerful Targeted Cancer Solutions

ADC  Cytotoxin with Linker

Enhanced Stability And Efficacy

ADC Linker

Precise Conjugation For Success

Antibody-Drug  Conjugates (ADCs)

Maximized Therapeutic Performance

Auristatins

Next-Level Tubulin Inhibition

Calicheamicins

High-Impact DNA Targeting

Camptothecins

Advanced Topoisomerase Inhibition

Daunorubicins / Doxorubicins

Trusted Anthracycline Payloads

Duocarmycins

Potent DNA Alkylation Agents

Maytansinoids

Superior Microtubule Disruption

Pyrrolobenzodiazepines

Ultra-Potent DNA Crosslinkers

Traditional Cytotoxic Agents

Proven Chemotherapy Solutions

Cleavable Linker

Precise Intracellular Drug Release

Non-Cleavable Linker

Exceptional Long-Term Stability

Historical Records: endo-BCN-PEG3-PFP ester | SuO-Glu-Val-Cit-PAB-MMAE | Me-triacetyl-β-D-glucopyranuronate-Ph-ald-NO2 | N-(2-(2,6-Dimethylphenoxy)ethyl)-4-Formylbenzamide | Seco-DUBA hydrochloride | Seco-DUBA | 2-(4-formylbenzamido)ethyl nitrate | Propargyl-O-C1-amido-PEG4-C2-NHS ester | Maytansinoid DM4 | Actinomycin D | Fmoc-N-Me-Lys(N3)-OH
Send Inquiry
Verification code
Inquiry Basket